Stephanie Wheeler, MD, MPH, FACP | Division of General Internal Medicine

Associate Professor

Medicine

Medical Director, Home Based Primary Care

Faculty Information

Biography

Education & Training:

University of Washington, School of Medicine

Seattle, WA

1989–1993

Residency in Primary Care Internal Medicine

University of Washington

Seattle, WA

1993–1996

Chief Residency in Internal Medicine

Boise VA Medical Center

Boise, ID

1995–1996

MPH

University of Washington, School of Public Health and Community Medicine

Seattle, WA

1998

Honors:

Fellow, National Research Service Award Program

1996–1998

Commendation from R. James Nicholson, Secretary of Veterans Affairs

2006

VAPSHCS Red Carpet Award

2008

VAPSHCS Performance Award

2008

Top Doctor, Seattle Metropolitan Magazine

2011

Service Award, VA Puget Sound Health Care System

2015

Fellow, American College of Physicians

2016

Top Doctor, VA Puget Sound

2018

Contact

Email:

Research & Clinical Interests

Clinical Interests:

Cardiovascular epidemiology
Diabetes

Publications

Publications:

Smith CS, Morris M, Hill W, Francovich C, McMullin J, Christiano J, Chavez L, Roth C, Vo A, Wheeler SG, Milne C. Testing the exportability of a tool for detecting operational problems in VA Teaching Clinics. Journal of General Internal Medicine. 2006; 21(2): 152–157.
Wheeler SG, Bowen J, Maynard C, Lowy E, Sun H, Sales AE, Smith NL, Fihn SD. Women veterans and outcomes after acute myocardial infarction. Journal of Women’s Health. 2009; 18(5): 613–618.
Wheeler SG, Ahroni J, Boyko E. Prospective study of autonomic neuropathy as a predictor of mortality in patients with diabetes. Diabetes Research and Clinical Practice. 2002; 58(2): 131–138.
Smith CS, Francovich C, Morris M, Hill W, Langlois-Winkle F, Rupper R, Roth C, Wheeler S, Vo A. Toward an ecological perspective of resident teaching clinic. Advances in Health Sciences Education. 2010; 15:771–778.
Wheeler SG, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, Boyko EJ. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 2013; 56: 1934–1943.